

Therapeutic Application of Lithium in Bipolar Disorders: A Brief Review

Review began 09/10/2022
Review ended 09/13/2022
Published 09/19/2022

© Copyright 2022

Kamal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Zubair Mahmood Kamal ¹, Siddhartha Dutta ², Sayeeda Rahman ³, Ayukafangha Etando ⁴, Emran Hasan ⁵, Sayeda Nazmun Nahar ⁶, Wan Farizatul Shima Wan Ahmad Fakuradzi ⁷, Susmita Sinha ⁸, Mainul Haque ⁹, Rahnuma Ahmad ¹⁰

1. Psychiatry, National Institute of Mental Health (NIMH), Dhaka, BGD 2. Department of Pharmacology, All India Institute of Medical Sciences, Rajkot, Rajkot, IND 3. School of Medicine, American University of Integrative Sciences, Bridgetown, BRB 4. Department of Medical Laboratory Sciences, Faculty of Health Sciences, Eswatini Medical Christian University, Mbabane, SWZ 5. Public Health, Institute of Epidemiology Disease Control and Research (IEDCR), Dhaka, BGD 6. Public Health, Save the Children Bangladesh, Dhaka, BGD 7. Community Medicine, Faculty of Medicine and Defence Health, National Defence University of Malaysia, Kuala Lumpur, MYS 8. Physiology, Khulna City Medical College and Hospital, Khulna, BGD 9. Pharmacology and Therapeutics, National Defence University of Malaysia, Kuala Lumpur, MYS 10. Department of Physiology, Medical College for Women and Hospital, Dhaka, BGD

Corresponding author: Mainul Haque, runurono@gmail.com

Abstract

Bipolar affective disorder includes Bipolar Disease (BD) and Bipolar Spectrum Disorder (BSD). The prevalence of BSD, BD-I, BD-II, and subthreshold BD globally is estimated to be about 3.1%, 1.5%, 0.03%, and 1.6%, respectively. BD is a multidimensional disease that exhibits a range of moods of mania, hypomania, and depression. The disease is chronic, complex, and fatal, with a high possibility of reappearance, infirmity, social incompetence, and *felo-de-se*. Managing emotional disruption, negative neuropsychology, physiology, and immunology is a challenge. This review focuses on therapeutic benefits, adverse drug reactions, and pharmacological intervention for BD and BSD, in particular lithium. Long-term management of BD with a single medication is ineffective and therefore, not recommended. It is advised to use multiple agents for treatment instead. Medications include mood stabilizers (lithium and anticonvulsants), atypical antipsychotics, and antidepressants. Along with medication provision, psychotherapy is of great significance for BD patients. The review was conducted on recent available scientific literature through the electronic database like Embase, ScienceDirect, Google Scholar, and PubMed using keywords like 'Bipolar Disease,' 'Bipolar Disease Therapeutics,' 'Bipolar Disease and Psychotherapy' to highlight the possible effective means of management of this disease of mood instability.

Categories: Family/General Practice, Psychiatry, Therapeutics

Keywords: nhs approved medications, fda-approved medications, treatment modalities, history of bipolar disorders, bipolar spectrum disorder, narrative review, bipolar disorders, lithium, intervention, pharmacological treatment

Introduction And Background

Globally, bipolar disorder (BD) and bipolar spectrum disorders (BSD) variants are of jeopardizing psychological diseases [1-3]. Worldwide recent guesstimates of BD lifetime prevalence for BSD, BD-I, BD-II, and sub-threshold BD were 3.1%, 1.5%, 0.03%, and 1.6%, respectively [4]. Multiple studies reported that 50-75% of all cases of BD and BSD live in low-middle-income countries (LMICs) and low-and lower-middle-income countries (LLMICs), and only 10% of them had reasonable healthcare access [3,5]. BD is a multidimensional disease that embraces a range of events (manic, hypomanic, and depressive) of dire emotional disruption. Furthermore, there are serious disturbances in neuropsychology, immunology, and physiology, thereby raising multiple disorders challenging to treat [2,6]. The etiopathogenesis of BD to date is poorly explained. It is frequently described genetic inheritances remain a substantial issue in developing BD [7,8]. It has been revealed that patients with BD and BSD suffer from miserable life patterns [9,10]. The disease affects patients' education, productiveness, performance, socialization, and close and affectionate kinship [9].

Pharmacological interventions remain the principal pillar of treatment options for BD, but drug therapy alone inadequately addresses the issue [11]. Moreover, there is a high possibility of recurrence, enduring symptoms, and psychopathological incapacitation [11]. Psychotherapy is a dynamic component in the overall management of BD [12] and must be available to patients and communities. A few different types of psychotherapy have been recommended and practiced for BD. These are interpersonal and social rhythm therapy (IPSRT), cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), group psychoeducation, and family-focused therapy (FFT) [11,13]. There are several classes of drugs used to treat BD [14]; among them, lithium (Li) is a classic drug that's used to treat this disease [15]. It's the most effective but possesses some serious toxicity [16].

Objectives of the study

How to cite this article

Kamal Z, Dutta S, Rahman S, et al. (September 19, 2022) Therapeutic Application of Lithium in Bipolar Disorders: A Brief Review. *Cureus* 14(9): e29332. DOI 10.7759/cureus.29332

This review focused on the therapeutic benefits and adverse drug reactions of pharmacological intervention of BD and BSD, particularly the therapeutic application of lithium.

Review

Historical perspective of bipolar disorders

It has been reported that human beings have been experiencing shifting moods and energy levels with a history of over thousands of years [17]. The alternating mood state as highs and lows, termed mania and melancholia, respectively, originated in ancient Greece [17,18]. Melancholia derives from the Greek words melas and chole, meaning "black" and "bile" or "gall," which refers to the compulsive state of severe despondency [19-21]. The word mania originates from the Greek phrase Ania and Manos, meaning "to produce great mental anguish" and "relaxed or lose," respectively [22]. The age-old concept of developing mania was believed as a result of the excessive amount of yellow bile in our system [23]. Additionally, it was presumed in the old days that mania and melancholia arose from imbalances in the body's humor [24-26]. Additionally, older concepts regarding mania and melancholia were because of excess amounts of yellow bile, and black bile, respectively [20,27,28]. A Greek Methodic named Soranus of Ephesus (98-177 CE {common or current era}) describes mania and melancholia as related disorders [29]. Later, Aretaeus of Cappadocia, the most outstanding medical scholar of the 2nd century of Greco-Roman culture, first talked about the BD [30,31].

The contemporary psychiatric comprehension of manic-depressive disease dates back to 1850 [32]. Jean-Pierre Falret (1794-1870), a French psychiatrist, described a novel psychiatric disorder named "folie circulaire" (circular insanity) which follows a cycle of depression, and mania, with a symptom-free interlude of the undetermined period amid these two ends of the disease [21,33-35]. Jules Gabriel François Baillarger (1809-1890), another French neurologist and psychiatrist, described a similar disorder as an alternating phase of mania and melancholia without any remission and termed "la folie à double forme" [36-38]. Emil Wilhelm Georg Magnus Kraepelin (1856-1926), a well-known and persuasive German expert in mental disorders, studied and cataloged the instinctive trajectory of BD and termed it as "manisch-depressives Irresein" (manic-depressive insanity) [39-42]. Dr. Emil Kraepelin is considered a post-Freudian father of modern scientific psychiatry because of his work [39]. He had differentiated dementia praecox (currently known as schizophrenia) and manic-depressive insanity (presently called BD or BSD) as two endogenous psychiatric entities [43,44].

Bipolar disorders and lithium initial findings

Initially, Li was utilized for the pharmacological management of uric acid calculi and gout. Nevertheless, it was thought to be toxic and ineffective [45]. However, lithium was efficacious for managing psychiatric diseases for over one hundred years [45]. An Australian psychiatrist named John Frederick Joseph Cade AO (1912-1980) had the first detailed positively regarding the pharmacology of lithium carbonate as a mood stabilizer for the therapeutic management of BD in 1948 [46]. Dr. John Cade found that lithium salt effectively controlled manic-depressive episodes of veterans of World War II [45,47]. The fear of lithium toxicity developed quickly, and Dr. Cade's positive findings were not accepted to be utilized clinically for years [48]. The medical community has accepted Li because Poul Christian Baastrup, Mogens Schou, and their colleagues' relentless work generated evidence of this medication's efficacy and safety [48-54].

Current pharmacological treatment modalities for bipolar diseases

BD is a chronic, complex, and fatal disease with high possibilities of reappearance, infirmity, social amateurishness, and felo-de-se [6,55]. The modalities of treatment are depicted in Figure 1. The pharmacological interventions of BD typically comprise conjunctions of no less than two medications [32,56]. Those medications include mood stabilizers (lithium and anticonvulsants {AC}), atypical antipsychotics, and antidepressants [57-59]. Depressive states are preliminary predominant features and frequently lead to the wrong diagnosis. Thereby, the commencement of mood stabilizing medication is commonly deferred, leading to complicated clinical scenarios [56]. Orthodox mood stabilizing agents are considered for first-line medicines [55]. At the same time, atypical antipsychotics (AP) are gradually increasingly being prescribed [56]. Selective serotonin reuptake inhibitors (SSRIs) are recommended as soon as mood stabilizers are ineffectual and when the depression returns among BD individuals [56].




FIGURE 1: Multimodal Treatment Strategies In Bipolar Disorders.

Image Credit: Siddhartha Dutta.

Table 1 illustrates medications approved by the United States of America (USA) Food and Drug Administration (FDA) [60]. Almost similar medication is approved by the National Health Service (NHS), the United Kingdom (UK) depicted in Table 2 [61].

Medication Category	Pharmacological Name and Year Licensed	Manic	Mixed (Mania/Depression)	Continual Medication	Depression
Mood Stabilizer	Lithium 1970	✓		✓	
Atypical Antipsychotics	Aripiprazole 2004	✓	✓	✓	
	Asenapine 2015	✓	✓		
	Cariprazine 2015				
	Lurasidone 2013				✓
	Olanzapine 2000	✓	✓	✓	
	Olanzapine/fluoxetine combination 2012				✓
	Quetiapine 2004	✓			✓
	Risperidone 2003	✓	✓		
	Ziprasidone 2004	✓	✓		
Anticonvulsants	Carbamazepine 2004	✓	✓		
	Lamotrigine 2003			✓	
	Sodium Valproate and Valproate Semisodium 1995	✓			
	Lamotrigine 2003			✓	

TABLE 1: FDA Approved Medications for Bipolar Disorder.

FDA: Food and Drug Administration

Medication Category	Pharmacological Name
Mood Stabilizer	Lithium
Antipsychotic Drugs	Aripiprazole
	Olanzapine
	Quetiapine
	Risperidone
	Carbamazepine
Anticonvulsants	Sodium Valproate
	Lamotrigine

TABLE 2: NHS Approved Medications For Bipolar Disorder.

NHS: National Health Service

Mode of action of lithium in bipolar disorder

Li is a monovalent (Li^+) alkali metal and is widely used for the treatment of BD [62]. This alkali metal has been used for almost 60 years for BD as the “gold standard” [63] for mood stabilization [64]. The pathogenesis of BD is complex [6]. Patients with bipolar affective disorder have reduced γ -aminobutyric acid (GABA) neurotransmission, which results in excitatory toxicity. GABA also modulates glutamate and dopamine [65]. Yet to date, the precise pharmacodynamics of lithium regarding BD is not completely elucidated [66]. Nevertheless, recent studies reported that Li persuades various biochemical processes at the cellular level through the modulation of neurotransmission [67,68].

Li^+ decreases excitatory neurotransmission at the cellular level by lowering dopamine and glutamate levels. It increases inhibitory transmission by increasing GABA and serotonin levels [66,67]. Li^+ increases GABA levels, thus directly activating GABA receptors and additionally reducing glutamate and down-regulate N-methyl D-aspartate (NMDA) receptors [66,69]. Li^+ alters neurotransmitter and receptor-mediated signaling systems, natural biological forces, hormonal and circadian controlling mechanisms, ion transportation, and gene expression [62,70]. Additionally, Li^+ targets two enzymatic pathways by inhibiting these enzymes to control BD. One is inositol monophosphatase within the phosphatidylinositol signaling pathway, and the second is the glycogen synthase kinase 3 [65]. Li^+ affects several second messenger systems. It mainly inhibits the breakdown of inositol monophosphate to inositol; this results in a decrease in free inositol and a subsequent decrease of phosphatidylinositol 4,5-biphosphate (PIP2) (Figure 2). The PIP2 is a precursor of second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG) in the cell membrane. These two second messengers are responsible for various effects. The PIP2-dependent pathways are thought to be increased in BD, so treatment with lithium is expected to decrease the activity in these pathways [71].




FIGURE 2: Illustration of Lithium Blocking the Breakdown of Inositol Monophosphate to Inositol.

The breakdown of inositol mono phosphate to inositol results in a decrease in free inositol and a subsequent decrease of phosphatidylinositol (PIP2).

Image Credit: Rahnuma Ahmad

PI C: Phospholipase C, IP3: Phosphatidyl Inositol triphosphate, DAG: Diacyl Glycerol, IP: Inositol Mono Phosphate, PIP: Phosphatidyl Inositol Phosphate, PIP2: Phosphatidyl Inositol Bis Phosphate.

Li initially retards the process of brain loss, primarily responsible for emotional activity among bipolar individuals. It has been reported that lithium possesses not only neuroprotective effects by conserving the brain structures but is also responsible for volumetric increase tangled with emotional control, for instance, the prefrontal cortex, hippocampus, amygdala, anterior cingulate, subgenual anterior cingulate cortex, inferior frontal gyrus, postcentral gyrus, and habenula (Figure 3) [72-74]. Li correspondingly kindles the generation of stem cells, including bone marrow and neural cells in the subventricular zone, striatum, and forebrain. The encouragement of natural neuronal stem cell formation suggests that Li increases brain tissue mass and capacity among BD individuals [75-77]. At the clinical level, Li is used to control mania; it prevents relapse, reduces suicidal drive in bipolar and unipolar depression, and treats bipolar depression. finally, it prevents bipolar-related cognitive decline at a population level [78,79]. The summary of the effects of lithium is depicted in Figure 4.




FIGURE 3: The Effects of Lithium on Brain.

This image is depicting the effects of Lithium on the brain including the Prefrontal Cortex, Cingulate Gyrus, Amygdala, Hippocampus, Habenula.

Image Credit: Rahnuma Ahmad.




FIGURE 4: Summary of Effects and Adverse Drug Reactions of Lithium.

Image Credit: Siddhartha Dutta.

BDNF and Bcl-2 are neuroprotective proteins.

Adverse effects of lithium in bipolar disorder

Li causes mild adverse drug reactions (ADRs) such as apprehension of sickness (feeble, fragile), frequent intestinal evacuations, frequent micturition, deterioration of existing tremor, mild ataxia, dental caries, inattentiveness, poor recall, dry mouth, and an erratic taste in the mouth [80-82]. Moderate ADRs of Li include confusion, agitation, delirium, tachycardia, and hypertonia. Severe ADRs of Li include coma, seizures, hyperthermia, and hypotension. The serum level of Li for mild, moderate, and severe ADRs were 1.5-2.5, 2.5-3.5, and over 3.5 mEq/L, respectively [83,84]. The effective pharmacotherapeutic range of Li for managing BD is 0.8-1.2 mEq/L [85-87].

Lithium vs. antipsychotics/anticonvulsants in bipolar disorder

A systematic review comprising eight real-life studies containing around 14,000 patients revealed that Li^+ had better clinical results than AC (valproate, lamotrigine, carbamazepine) and atypical AP (olanzapine, quetiapine) [88]. Another study reported that lithium remains the gold standard therapeutic agent for BD despite rising evidence and availability of AC and atypical APs. Nevertheless, it has been recommended that a single medication for the long-standing management of BD is considered ineffective. Multiple agents have been advised for treatment-refractory and rapid-cycling forms of BD [89,90]. However, a study compared different treatment regimens and reported that those patients under Li^+ + AC (principally lamotrigine and valproate) and Li^+ + AP (mainly quetiapine and aripiprazole) + AC exhibited a poorer quality clinical outcome than those Li^+ prescribed as a single agent ($p < 0.01$) [91].

Additionally, it was shown that Li^+ + AP is better in managing BD patients, especially in general ($p = 0.05$) and manic ($p = 0.01$) symptoms than Li^+ + AC. Unfortunately, ADRs due to APs were noticed to cause metabolic syndrome, especially in glucose and triglycerides [91]. Antipsychotics of the second generation are progressively more prescribed as a single agent or parallelly in combination with other medication for maintenance therapy in BD [92,93]. These newer antipsychotics are considered a single class. Nonetheless, their pharmacokinetics, pharmacodynamics, and ADRs regarding BD have wide-ranging variations [94]. It has been reported that quetiapine, asenapine, and lurasidone show better preventive potential towards depressive episodes of BD [95-99]. Additionally, antipsychotics are the rational alternative for patients with BD who are oversensitive or have poor compliance to Li therapy for relapse prevention (Figure 5) [99,100].




FIGURE 5: Lithium Versus Antipsychotics in Bipolar Disorder.

BD: Bipolar disorder

Image Credit: Susmita Sinha.

Cost-effectiveness of therapeutic modalities for bipolar mood disorder

Family-based treatment for BD was more effective than hospitalized treatment [101]. This research also recommended that a community-focused mental health program with Li and psychotherapy was found to be the most economical for the prevention of relapse among BD patients [101]. It has been reported that quetiapine + Li^+ or divalproex Na^+ possesses better clinical outcomes over placebo + Li^+ or divalproex Na^+ when considered “probabilistic sensitivity analysis (PSA)” among BD [102,103]. Furthermore, quetiapine + Li^+ or divalproex Na^+ regimen demonstrated in minimizing severe manic events (46%), critical depressive occurrences (41%), and hospital stay (44%) than placebo + Li^+ or divalproex Na^+ [102]. Thereby, the quetiapine + Li^+ or divalproex Na^+ regime showed more cost-efficient long-term therapeutic intervention among bipolar I diseases [102,104]. One pharmaco-economic research paper evaluating quetiapine cost-efficiency as an ancillary medication with Li^+ among British and American BD type I cases for long-term pharmacological intervention found a positive result [105].

Furthermore, for BD type II, cost-efficiency is not similarly robust evidence for maintenance therapy over two years [96]. Another European study reported that quetiapine + Li^+ or valproate Na^+ decreases acute manic episodes (54%), related hospital stay (29%), improves the quality-adjusted life year (QALY) by 4%, and

reduces financial overhead by 5% in comparison to placebo + Li⁺ or valproate Na⁺ among BD type I [106]. Another pharmaco-economic study reported that quetiapine was more cost-efficient than olanzapine in the therapeutic intervention among depressive BD [107]. One British study evaluating pharmaco-economic issues among BD type I with manic, mixed, or hypomanic events reported that the Li⁺+ lamotrigine combination remains the most cost-efficient [108]. This combination (Li⁺+ lamotrigine) also potentially defers relapse or recurrence of manic or hypomanic events among BD type I [109].

Role of psychotherapy in bipolar mood disorder

The pharmacological therapeutic options of BD have improved at significant paces [32,110]. Nevertheless, it has been reported that medication alone cannot maintain health-related quality of life (HRQOL) in most cases of BD. These patients need psychotherapy besides drug intervention [111,112]. Long before, psychotherapy was endorsed as an auxiliary therapeutic modality in addition to pharmacological management of BD [113]. Multiple studies reported that the psychotherapeutic approach with close relatives, fellow or kin support, in addition to medication, improves cognitive performances and enhances self-dependency skills among BD cases [11,114-116]. Psychological treatment options, especially cognitive behavioral therapy, are potentially effective in managing depressive events [117-119]. Several studies revealed that psychoeducation is more helpful among patients with manic symptoms of BD. As these patients learn early features of manic episodes, substantial improvements are achieved in socialization and employment [120-122]. Psychoeducation combines cognitive-behavioral therapy, group therapy, and education intervention [123,124]. It has been reported that as psychotherapies reduce hospital stay and improve socialization and employability skills, the psychological therapeutic approach is considered cost-efficient for BD management and other psychiatric issues (Figure 6) [125-127].




FIGURE 6: Schematic Diagram Showing Effects of Various Therapies in Bipolar Mood Disorder.

Image Credit: Susmita Sinha.

Conclusions

It is evident that lithium exerts a wide range of therapeutic effects on mood and cognition through a

complicated network of actions, including neurotransmission and cellular signaling pathways. Therapeutic strategies are still the major focus of BD therapeutic approaches, but drug therapy alone is insufficient for addressing the problem. Lithium appears harmful in studies of cognition in non-psychiatric people, but it seems effective in BD patients. Additionally, it was observed that a community-focused mental health program using Li⁺ and psychotherapy was extremely cost-effective for the prevention of relapsing in BD. Most instances of BD require psychotherapy because medication alone cannot preserve the health-related quality of life. Cross techniques must be used in research and the most recent technological advances in fields like neuroimaging and genetics, in addition to a thorough evaluation of patients with BD. Therefore, by combining basic science research and clinical studies, a more complete picture of the actions of this enigmatic element, Lithium, will spring up.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Harrison PJ, Geddes JR, Tunbridge EM: The emerging neurobiology of bipolar disorder . *Trends Neurosci.* 2018, 41:18-30. [10.1016/j.tins.2017.10.006](https://doi.org/10.1016/j.tins.2017.10.006)
- Rowland TA, Marwaha S: Epidemiology and risk factors for bipolar disorder . *Ther Adv Psychopharmacol.* 2018, 8:251-69. [10.1177/2045125318769235](https://doi.org/10.1177/2045125318769235)
- Godman B, Grobler C, Van-De-Lisle M, et al.: Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. *Expert Opin Pharmacother.* 2019, 20:2237-55. [10.1080/14656566.2019.1684473](https://doi.org/10.1080/14656566.2019.1684473)
- Teh WL, Abdin E, Vaingankar J, et al.: Prevalence and correlates of bipolar spectrum disorders in Singapore: Results from the 2016 Singapore Mental Health Study (SMHS 2016). *J Affect Disord.* 2020, 274:339-46. [10.1016/j.jad.2020.05.032](https://doi.org/10.1016/j.jad.2020.05.032)
- Arnbjerg CJ, Rurangwa NU, Musoni-Rwililiza E, Gishoma D, Carlsson J, Kallestrup P: Intervention trials for adults with bipolar disorder in low-income and lower-middle-income countries: a systematic review. *J Affect Disord.* 2022, 311:256-66. [10.1016/j.jad.2022.05.097](https://doi.org/10.1016/j.jad.2022.05.097)
- Jain A, Mitra P: *Bipolar Affective Disorder*. StatPearls Publishing [Internet], Treasure Island (FL); 2022.
- Escamilla MA, Zavala JM: Genetics of bipolar disorder. *Dialogues Clin Neurosci.* 2008, 10:141-52. [10.31887/DCNS.2008.10.2/maescamilla](https://doi.org/10.31887/DCNS.2008.10.2/maescamilla)
- Barnett JH, Smoller JW: The genetics of bipolar disorder . *Neuroscience.* 2009, 164:331-43. [10.1016/j.neuroscience.2009.03.080](https://doi.org/10.1016/j.neuroscience.2009.03.080)
- Anyayo L, Ashaba S, Kaggwa MM, Maling S, Nakimuli-Mpungu E: Health-related quality of life among patients with bipolar disorder in rural southwestern Uganda: a hospital based cross sectional study. *Health Qual Life Outcomes.* 2021, 19:84. [10.1186/s12955-021-01729-5](https://doi.org/10.1186/s12955-021-01729-5)
- Sylvia LG, Montana RE, Deckersbach T, et al.: Poor quality of life and functioning in bipolar disorder . *Int J Bipolar Disord.* 2017, 5:10. [10.1186/s40345-017-0078-4](https://doi.org/10.1186/s40345-017-0078-4)
- Swartz HA, Swanson J: Psychotherapy for bipolar disorder in adults: a review of the evidence . *Focus (Am Psychiatr Publ).* 2014, 12:251-66. [10.1176/appi.focus.12.3.251](https://doi.org/10.1176/appi.focus.12.3.251)
- Goldstein TR, Fersch-Podrat RK, Rivera M, et al.: Dialectical behavior therapy for adolescents with bipolar disorder: results from a pilot randomized trial. *J Child Adolesc Psychopharmacol.* 2015, 25:140-9. [10.1089/cap.2013.0145](https://doi.org/10.1089/cap.2013.0145)
- Picardi A, Gaetano P: Psychotherapy of mood disorders . *Clin Pract Epidemiol Ment Health.* 2014, 10:140-58. [10.2174/1745017901410010140](https://doi.org/10.2174/1745017901410010140)
- Bauer M, Glenn T, Alda M, et al.: Drug treatment patterns in bipolar disorder: analysis of long-term self-reported data. *Int J Bipolar Disord.* 2013, 1:5. [10.1186/2194-7511-1-5](https://doi.org/10.1186/2194-7511-1-5)
- Zivanovic O: Lithium: a classic drug-frequently discussed, but, sadly, seldom prescribed! . *Aust N Z J Psychiatry.* 2017, 51:886-96. [10.1177/0004867417695889](https://doi.org/10.1177/0004867417695889)
- Licht RW: Lithium: still a major option in the management of bipolar disorder . *CNS Neurosci Ther.* 2012, 18:219-26. [10.1111/j.1755-5949.2011.00260.x](https://doi.org/10.1111/j.1755-5949.2011.00260.x)
- Mason BL, Brown ES, Croarkin PE: Historical underpinnings of bipolar disorder diagnostic criteria . *Behav Sci (Basel).* 2016, 6:[10.3390/bs6030014](https://doi.org/10.3390/bs6030014)
- Marlier K. *Melancholia and Mania: The Historical Contributions of Aretaeus of Cappadocia and Emil Kraepelin.* (2020). Accessed: July 23, 2021: <http://hdl.handle.net/1880/111923>.
- Ventriglio A, Bhugra D, Sampogna G, Luciano M, De Berardis D, Sani G, Fiorillo A: From dysthymia to treatment-resistant depression: evolution of a psychopathological construct. *Int Rev Psychiatry.* 2020, 32:471-6. [10.1080/09540261.2020.1765517](https://doi.org/10.1080/09540261.2020.1765517)
- Verplaetse J: Wild melancholy. On the historical plausibility of a black bile theory of blood madness, or hæmatomania. *Hist Psychiatry.* 2020, 31:151-46. [10.1177/0957154X19898653](https://doi.org/10.1177/0957154X19898653)
- Angst J, Marneros A: Bipolarity from ancient to modern times: conception, birth and rebirth . *J Affect Disord.* 2001, 67:3-19. [10.1016/s0165-0327\(01\)00429-3](https://doi.org/10.1016/s0165-0327(01)00429-3)
- Angst J, Sellaro R: Historical perspectives and natural history of bipolar disorder . *Biol Psychiatry.* 2000, 48:445-57. [10.1016/s0006-3223\(00\)00909-4](https://doi.org/10.1016/s0006-3223(00)00909-4)

23. Engelhardt E, Sudo FK, Alves GS, Laks J: Neuropsychiatric symptoms in brain diseases - historical foundations. *Dement Neuropsychol*. 2020, 14:324-8. [10.1590/1980-57642020dn14-030014](https://doi.org/10.1590/1980-57642020dn14-030014)
24. Kraepelin E, : Manic-depressive insanity and paranoia. *Ind Med Gaz*. 1921, 56:156-7.
25. Jansson Å: Introduction: Disordered Mood as Historical Problem . From Melancholia to Depression. *Mental Health in Historical Perspective*. Palgrave Macmillan, Cham; 2021. [10.1007/978-3-030-54802-5_1](https://doi.org/10.1007/978-3-030-54802-5_1)
26. Ross CA, Margolis RL: Research domain criteria: cutting edge neuroscience or Galen's humors revisited? . *Mol Neuropsychiatry*. 2018, 4:158-63. [10.1159/000493685](https://doi.org/10.1159/000493685)
27. Telles-Correia D, Marques JG: Melancholia before the twentieth century: fear and sorrow or partial insanity?. *Front Psychol*. 2015, 6:81. [10.3389/fpsyg.2015.00081](https://doi.org/10.3389/fpsyg.2015.00081)
28. Riva MA, Ferraina F, Paleari A, Lenti MV, Di Sabatino A: From sadness to stiffness: the spleen's progress . *Intern Emerg Med*. 2019, 14:739-43. [10.1007/s11739-019-02115-2](https://doi.org/10.1007/s11739-019-02115-2)
29. Sani G, Kotzalidis GD, Girardi P: Editorial: "The faces of mania: the legacy of Athanasios Koukopoulos" . *Curr Neuropharmacol*. 2017, 15:334-7. [10.2174/1570159X1503170228185225](https://doi.org/10.2174/1570159X1503170228185225)
30. Putri IV, Effendy E: Expressed emotion in a woman with bipolar disorder: a case report from Deli Serdang . *Open Access Maced J Med Sci*. 2019, 7:2671-4. [10.3889/oamjms.2019.400](https://doi.org/10.3889/oamjms.2019.400)
31. Tekiner H: Aretaeus of Cappadocia and his treatises on diseases . *Turk Neurosurg*. 2015, 25:508-12. [10.5137/1019-5149.JTN.12347-14.0](https://doi.org/10.5137/1019-5149.JTN.12347-14.0)
32. López-Muñoz F, Shen WW, D'Ocon P, Romero A, Álamo C: A history of the pharmacological treatment of bipolar disorder. *Int J Mol Sci*. 2018, 19: [10.3390/ijms19072143](https://doi.org/10.3390/ijms19072143)
33. Kendler KS: The genealogy of major depression: symptoms and signs of melancholia from 1880 to 1900 . *Mol Psychiatry*. 2017, 22:1539-53. [10.1038/mp.2017.148](https://doi.org/10.1038/mp.2017.148)
34. Angst J: Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia . *Schizophr Res*. 2002, 57:5-13. [10.1016/s0920-9964\(02\)00328-6](https://doi.org/10.1016/s0920-9964(02)00328-6)
35. Sedler MJ: Falret's discovery: the origin of the concept of bipolar affective illness. Translated by M. J. Sedler and Eric C. Dessain. *Am J Psychiatry*. 1983, 140:1127-33. [10.1176/ajp.140.9.1127](https://doi.org/10.1176/ajp.140.9.1127)
36. Benazzi F, Akiskal HS: Biphasic course in bipolar II outpatients: prevalence and clinical correlates of a cyclic pattern described by Baillarger and Falret in hospitalised patients in 1854. *J Affect Disord*. 2006, 96:183-7. [10.1016/j.jad.2004.04.005](https://doi.org/10.1016/j.jad.2004.04.005)
37. Pichot P: Circular insanity, 150 years on (Article in French) . *Bull Acad Natl Med*. 2004, 188:275-84.
38. Haustgen T, Akiskal H: French antecedents of "contemporary" concepts in the American Psychiatric Association's classification of bipolar (mood) disorders. *J Affect Disord*. 2006, 96:149-63. [10.1016/j.jad.2006.09.014](https://doi.org/10.1016/j.jad.2006.09.014)
39. Kendler KS: Kraepelin's final views on manic-depressive illness. *J Affect Disord*. 2021, 282:979-90. [10.1016/j.jad.2020.12.200](https://doi.org/10.1016/j.jad.2020.12.200)
40. Rybakowski JK: 120th anniversary of the Kraepelinian dichotomy of psychiatric disorders . *Curr Psychiatry Rep*. 2019, 21:65. [10.1007/s11920-019-1048-6](https://doi.org/10.1007/s11920-019-1048-6)
41. Rybakowski J: Etiopathogenesis of bipolar affective disorder - the state of the art for 2021 . *Psychiatr Pol*. 2021, 55:481-96. [10.12740/PP/132961](https://doi.org/10.12740/PP/132961)
42. Decker HS: The psychiatric works of Emil Kraepelin: a many-faceted story of modern medicine . *J Hist Neurosci*. 2004, 13:248-76. [10.1080/09647040490510470](https://doi.org/10.1080/09647040490510470)
43. Engstrom EJ: Tempering madness: Emil Kraepelin's research on affective disorders. *Osiris*. 2016, 31:163-80.
44. Ebert A, Bär KJ: Emil Kraepelin: a pioneer of scientific understanding of psychiatry and psychopharmacology. *Indian J Psychiatry*. 2010, 52:191-2. [10.4103/0019-5545.64591](https://doi.org/10.4103/0019-5545.64591)
45. Shorter E: The history of lithium therapy. *Bipolar Disord*. 2009, 11 Suppl 2:4-9. [10.1111/j.1399-5618.2009.00706.x](https://doi.org/10.1111/j.1399-5618.2009.00706.x)
46. CA JF: Lithium salts in the treatment of psychotic excitement . *Med J Aust*. 1949, 2:349-52. [10.1080/j.1440-1614.1999.06241.x](https://doi.org/10.1080/j.1440-1614.1999.06241.x)
47. Cole N, Parker G: Cade's identification of lithium for manic-depressive illness--the prospector who found a gold nugget. *J Nerv Ment Dis*. 2012, 200:1101-4. [10.1097/NMD.0b013e318275d3cb](https://doi.org/10.1097/NMD.0b013e318275d3cb)
48. Mitchell PB, Hadzi-Pavlovic D: Lithium treatment for bipolar disorder. *Bull World Health Organ*. 2000, 78:515-7.
49. Bastrup PC, Schou M: Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. *Arch Gen Psychiatry*. 1967, 16:162-72. [10.1001/archpsyc.1967.01730200030005](https://doi.org/10.1001/archpsyc.1967.01730200030005)
50. Bastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A: Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. *Lancet*. 1970, 2:326-30. [10.1016/s0140-6736\(70\)92870-9](https://doi.org/10.1016/s0140-6736(70)92870-9)
51. Schou M: Lithium treatment at 52. *J Affect Disord*. 2001, 67:21-32. [10.1016/s0165-0327\(01\)00380-9](https://doi.org/10.1016/s0165-0327(01)00380-9)
52. Schou M: The early European lithium studies . *Aust N Z J Psychiatry*. 1999, 33 Suppl:S39-47. [10.1111/j.1440-1614.1999.00667.x](https://doi.org/10.1111/j.1440-1614.1999.00667.x)
53. Schou M: Lithium in manic-depressive illness: plusses, pitfalls, and perspectives . *Psychopharmacol Ser*. 1988, 5:140-6. [10.1007/978-3-642-73280-5_13](https://doi.org/10.1007/978-3-642-73280-5_13)
54. Schou M: Prophylactic lithium treatment of unipolar and bipolar manic-depressive illness . *Psychopathology*. 1995, 28 Suppl 1:81-5. [10.1159/000284961](https://doi.org/10.1159/000284961)
55. Shah N, Grover S, Rao GP: Clinical practice guidelines for management of bipolar disorder. *Indian J Psychiatry*. 2017, 59:S51-66. [10.4103/0019-5545.196974](https://doi.org/10.4103/0019-5545.196974)
56. Thase ME: Pharmacotherapy of bipolar depression: an update . *Curr Psychiatry Rep*. 2006, 8:478-88. [10.1007/s11920-006-0055-6](https://doi.org/10.1007/s11920-006-0055-6)
57. Jann MW: Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. *Am Health Drug Benefits*. 2014, 7:489-99.
58. Vieta E, Valenti M: Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. *CNS Drugs*. 2013, 27:515-29. [10.1007/s40263-013-0073-y](https://doi.org/10.1007/s40263-013-0073-y)
59. Gitlin MJ: Antidepressants in bipolar depression: an enduring controversy . *Int J Bipolar Disord*. 2018, 6:25. [10.1186/s40345-018-0133-9](https://doi.org/10.1186/s40345-018-0133-9)
60. Butler M, Urosecvic S, Desai P, et al.: Treatment for Bipolar Disorder in Adults: A Systematic Review

- [Internet]. 2018 (ed): Agency for Healthcare Research and Quality (US), Rockville (MD); 2018.
61. Treatment - Bipolar disorder. (2022). Accessed: July 26, 2022: <https://www.nhs.uk/mental-health/conditions/bipolar-disorder/treatment/> .
 62. Machado-Vieira R, Manji HK, Zarate CA Jr: The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. *Bipolar Disord.* 2009, 11 Suppl 2:92-109. [10.1111/j.1399-5618.2009.00714.x](https://doi.org/10.1111/j.1399-5618.2009.00714.x)
 63. Tondo L, Alda M, Bauer M, et al.: Clinical use of lithium salts: guide for users and prescribers . *Int J Bipolar Disord.* 2019, 7:16. [10.1186/s40345-019-0151-2](https://doi.org/10.1186/s40345-019-0151-2)
 64. Volkmann C, Bschor T, Köhler S: Lithium treatment over the lifespan in bipolar disorders . *Front Psychiatry.* 2020, 11:377. [10.3389/fpsy.2020.00377](https://doi.org/10.3389/fpsy.2020.00377)
 65. Brown KM, Tracy DK: Lithium: the pharmacodynamic actions of the amazing ion . *Ther Adv Psychopharmacol.* 2013, 3:163-76. [10.1177/2045125312471963](https://doi.org/10.1177/2045125312471963)
 66. Malhi GS, Tanius M, Das P, Coulston CM, Berk M: Potential mechanisms of action of lithium in bipolar disorder. Current understanding. *CNS Drugs.* 2013, 27:135-53. [10.1007/s40263-013-0039-0](https://doi.org/10.1007/s40263-013-0039-0)
 67. Rijal S, Jang SH, Park SJ, Han SK: Lithium enhances the GABAergic synaptic activities on the hypothalamic preoptic area (hPOA) neurons. *Int J Mol Sci.* 2021, 22:3908. [10.3390/ijms22083908](https://doi.org/10.3390/ijms22083908)
 68. Brady RO Jr, McCarthy JM, Prescott AP, et al.: Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. *Bipolar Disord.* 2013, 15:434-9. [10.1111/bdi.12074](https://doi.org/10.1111/bdi.12074)
 69. Basselin M, Chang L, Bell JM, Rapoport SI: Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. *Neuropsychopharmacology.* 2006, 31:1659-74. [10.1038/sj.npp.1300920](https://doi.org/10.1038/sj.npp.1300920)
 70. Manji HK, Lenox RH: Signaling: cellular insights into the pathophysiology of bipolar disorder . *Biol Psychiatry.* 2000, 48:518-30. [10.1016/S0006-3223\(00\)00929-X](https://doi.org/10.1016/S0006-3223(00)00929-X)
 71. Can A, Schulze TG, Gould TD: Molecular actions and clinical pharmacogenetics of lithium therapy . *Pharmacol Biochem Behav.* 2014, 123:3-16. [10.1016/j.pbb.2014.02.004](https://doi.org/10.1016/j.pbb.2014.02.004)
 72. Hajek T, Weiner MW: Neuroprotective effects of lithium in human brain? Food for thought . *Curr Alzheimer Res.* 2016, 13:862-72. [10.2174/1567205013666160219112712](https://doi.org/10.2174/1567205013666160219112712)
 73. Forlenza OV, De-Paula VJ, Diniz BS: Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. *ACS Chem Neurosci.* 2014, 5:443-50. [10.1021/cn5000309](https://doi.org/10.1021/cn5000309)
 74. Bauer M, Alda M, Priller J, Young LT: Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. *Pharmacopsychiatry.* 2003, 36 Suppl 3:S250-4. [10.1055/s-2003-45138](https://doi.org/10.1055/s-2003-45138)
 75. Young W: Review of lithium effects on brain and blood . *Cell Transplant.* 2009, 18:951-75. [10.3727/096368909X471251](https://doi.org/10.3727/096368909X471251)
 76. Su H, Chu TH, Wu W: Lithium enhances proliferation and neuronal differentiation of neural progenitor cells in vitro and after transplantation into the adult rat spinal cord. *Exp Neurol.* 2007, 206:296-307. [10.1016/j.expneurol.2007.05.018](https://doi.org/10.1016/j.expneurol.2007.05.018)
 77. Su H, Zhang W, Guo J, Guo A, Yuan Q, Wu W: Lithium enhances the neuronal differentiation of neural progenitor cells in vitro and after transplantation into the avulsed ventral horn of adult rats through the secretion of brain-derived neurotrophic factor. *J Neurochem.* 2009, 108:1385-98. [10.1111/j.1471-4159.2009.05902.x](https://doi.org/10.1111/j.1471-4159.2009.05902.x)
 78. Benard V, Vaiva G, Masson M, Geoffroy PA: Lithium and suicide prevention in bipolar disorder . *Encephale.* 2016, 42:234-41. [10.1016/j.encep.2016.02.006](https://doi.org/10.1016/j.encep.2016.02.006)
 79. Sarai SK, Mekala HM, Lippmann S: Lithium suicide prevention: a brief review and reminder . *Innov Clin Neurosci.* 2018, 15:30-2.
 80. Gitlin M: Lithium side effects and toxicity: prevalence and management strategies . *Int J Bipolar Disord.* 2016, 4:27. [10.1186/s40345-016-0068-y](https://doi.org/10.1186/s40345-016-0068-y)
 81. Terao T, Watanabe S, Hoaki N, Hoaki T: Strange taste and mild lithium intoxication . *BMJ Case Rep.* 2011, 2011:[10.1136/bcr.05.2011.4267](https://doi.org/10.1136/bcr.05.2011.4267)
 82. Hedy SA, Avula A, Swoboda HD: Lithium Toxicity. StatPearls Publishing [Internet], Treasure Island (FL); 2022.
 83. Dunne FJ: Lithium toxicity: the importance of clinical signs . *Br J Hosp Med (Lond).* 2010, 71:206-10. [10.12968/hmed.2010.71.4.47513](https://doi.org/10.12968/hmed.2010.71.4.47513)
 84. Seŋga MM, Sarapuddin G, Sanieel E: A case report on an atypical presentation of the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT) in a war veteran with bipolar disorder and PTSD. *Case Rep Psychiatry.* 2020, 2020:5369297. [10.1155/2020/5369297](https://doi.org/10.1155/2020/5369297)
 85. Reddy DS, Reddy MS: Serum lithium levels: ideal time for sample collection! are we doing it right? . *Indian J Psychol Med.* 2014, 36:346-7. [10.4103/0253-7176.135399](https://doi.org/10.4103/0253-7176.135399)
 86. Severus WE, Kleindienst N, Seemüller F, Frangou S, Möller HJ, Greil W: What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review?. *Bipolar Disord.* 2008, 10:231-7. [10.1111/j.1399-5618.2007.00475.x](https://doi.org/10.1111/j.1399-5618.2007.00475.x)
 87. Nolen WA, Licht RW, Young AH, et al.: What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. *Bipolar Disord.* 2019, 21:394-409. [10.1111/bdi.12805](https://doi.org/10.1111/bdi.12805)
 88. Kessing LV, Bauer M, Nolen WA, Severus E, Goodwin GM, Geddes J: Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. *Bipolar Disord.* 2018, [10.1111/bdi.12623](https://doi.org/10.1111/bdi.12623)
 89. Muzina DJ, Calabrese JR: Maintenance therapies in bipolar disorder: focus on randomized controlled trials . *Aust N Z J Psychiatry.* 2005, 39:652-61. [10.1080/j.1440-1614.2005.01649.x](https://doi.org/10.1080/j.1440-1614.2005.01649.x)
 90. Bowden CL: Acute and maintenance treatment with mood stabilizers . *Int J Neuropsychopharmacol.* 2003, 6:269-75. [10.1017/S1461145705003535](https://doi.org/10.1017/S1461145705003535)
 91. Köhler-Forsberg O, Sylvia LG, Thase M, et al.: Lithium plus antipsychotics or anticonvulsants for bipolar disorder: comparing clinical response and metabolic changes. *Aust N Z J Psychiatry.* 2022, [48674221077619](https://doi.org/10.1111/bdi.12805).

- [10.1177/00048674221077619](https://doi.org/10.1177/00048674221077619)
92. Schwartz TL, Stahl SM: Treatment strategies for dosing the second generation antipsychotics . *CNS Neurosci Ther.* 2011, 17:110-7. [10.1111/j.1755-5949.2011.00234.x](https://doi.org/10.1111/j.1755-5949.2011.00234.x)
 93. Chokhawala K, Stevens L: *Antipsychotic Medications*. StatPearls Publishing [Internet], Treasure Island (FL); 2022.
 94. Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, Altamura AC: Clinical pharmacology of atypical antipsychotics: an update. *EXCLI J.* 2014, 13:1163-91.
 95. Franklin R, Zorowitz S, Corse AK, Widge AS, Deckersbach T: Lurasidone for the treatment of bipolar depression: an evidence-based review. *Neuropsychiatr Dis Treat.* 2015, 11:2143-52. [10.2147/NDT.S50961](https://doi.org/10.2147/NDT.S50961)
 96. Muneer A: Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update . *Clin Psychopharmacol Neurosci.* 2015, 13:25-35. [10.9758/cpn.2015.13.1.25](https://doi.org/10.9758/cpn.2015.13.1.25)
 97. Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J: Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. *BMC Psychiatry.* 2011, 11:101. [10.1186/1471-244X-11-101](https://doi.org/10.1186/1471-244X-11-101)
 98. De Filippis S, Cuomo I, Kotzalidis GD, et al.: Does the efficacy of asenapine in bipolar disorder increase in the presence of comorbidity with a substance use disorder? A naturalistic study. *Ther Adv Psychopharmacol.* 2017, 7:67-77. [10.1177/2045125316674698](https://doi.org/10.1177/2045125316674698)
 99. Stroup TS, Gray N: Management of common adverse effects of antipsychotic medications . *World Psychiatry.* 2018, 17:341-56. [10.1002/wps.20567](https://doi.org/10.1002/wps.20567)
 100. Wunderink L: Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders. *Ther Adv Psychopharmacol.* 2019, 9:2045125319836566. [10.1177/2045125319836566](https://doi.org/10.1177/2045125319836566)
 101. Chisholm D, van Ommeren M, Ayuso-Mateos JL, Saxena S: Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. *Br J Psychiatry.* 2005, 187:559-67. [10.1192/bjp.187.6.559](https://doi.org/10.1192/bjp.187.6.559)
 102. Woodward TC, Tafesse E, Quon P, Kim J, Lazarus A: Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder. *J Med Econ.* 2009, 12:259-68. [10.3111/13696990903266612](https://doi.org/10.3111/13696990903266612)
 103. Vieta E, Suppes T, Eggers I, Persson I, Paulsson B, Brecher M: Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). *J Affect Disord.* 2008, 109:251-63. [10.1016/j.jad.2008.06.001](https://doi.org/10.1016/j.jad.2008.06.001)
 104. Woodward TC, Tafesse E, Quon P, Lazarus A: Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. *Pharmacoeconomics.* 2010, 28:751-64. [10.2165/11538350-000000000-00000](https://doi.org/10.2165/11538350-000000000-00000)
 105. Plosker GL: Quetiapine: a pharmacoeconomic review of its use in bipolar disorder . *Pharmacoeconomics.* 2012, 30:611-31. [10.2165/11208500-000000000-00000](https://doi.org/10.2165/11208500-000000000-00000)
 106. Fajutrao L, Paulsson B, Liu S, Locklear J: Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. *Clin Ther.* 2009, 31 Pt 1:1456-68. [10.1016/j.clinthera.2009.06.009](https://doi.org/10.1016/j.clinthera.2009.06.009)
 107. Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC, Chatterton ML: Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. *Pharmacoeconomics.* 2012, 30:513-30. [10.2165/11594930-000000000-00000](https://doi.org/10.2165/11594930-000000000-00000)
 108. Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR: The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. *J Manag Care Pharm.* 2006, 12:322-30. [10.18553/jmcp.2006.12.4.322](https://doi.org/10.18553/jmcp.2006.12.4.322)
 109. Bowden CL, Calabrese JR, Sachs G, et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. *Arch Gen Psychiatry.* 2003, 60:392-400. [10.1001/archpsyc.60.4.392](https://doi.org/10.1001/archpsyc.60.4.392)
 110. Yalin N, Young AH: Pharmacological treatment of bipolar depression: what are the current and emerging options?. *Neuropsychiatr Dis Treat.* 2020, 16:1459-72. [10.2147/NDT.S245166](https://doi.org/10.2147/NDT.S245166)
 111. Kamenov K, Twomey C, Cabello M, Prina AM, Ayuso-Mateos JL: The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. *Psychol Med.* 2017, 47:414-25. [10.1017/S0033291716002774](https://doi.org/10.1017/S0033291716002774)
 112. Bonnín CD, Reinares M, Martínez-Arán A, et al.: Improving functioning, quality of life, and well-being in patients with bipolar disorder. *Int J Neuropsychopharmacol.* 2019, 22:467-77. [10.1093/ijnp/pyz018](https://doi.org/10.1093/ijnp/pyz018)
 113. Miklowitz DJ: Adjunctive psychotherapy for bipolar disorder: state of the evidence . *Am J Psychiatry.* 2008, 165:1408-19. [10.1176/appi.ajp.2008.08040488](https://doi.org/10.1176/appi.ajp.2008.08040488)
 114. Gitlin M: Treatment-resistant bipolar disorder. *Mol Psychiatry.* 2006, 11:227-40. [10.1038/sj.mp.4001793](https://doi.org/10.1038/sj.mp.4001793)
 115. Proudfoot J, Parker G, Manicavasagar V, et al.: Effects of adjunctive peer support on perceptions of illness control and understanding in an online psychoeducation program for bipolar disorder: a randomised controlled trial. *J Affect Disord.* 2012, 142:98-105. [10.1016/j.jad.2012.04.007](https://doi.org/10.1016/j.jad.2012.04.007)
 116. Novick DM, Swartz HA: Evidence-based psychotherapies for bipolar disorder . *Focus (Am Psychiatr Publ).* 2019, 17:238-48. [10.1176/appi.focus.20190004](https://doi.org/10.1176/appi.focus.20190004)
 117. Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A: Adjunctive psychotherapy for bipolar disorder: a systematic review and component network meta-analysis. *JAMA Psychiatry.* 2021, 78:141-50. [10.1001/jamapsychiatry.2020.2993](https://doi.org/10.1001/jamapsychiatry.2020.2993)
 118. Özdel K, Kart A, Türkçapar MH: Cognitive behavioral therapy in treatment of bipolar disorder . *Noro Psikiyatir Ars.* 2021, 58:S66-76. [10.29399/npa.27419](https://doi.org/10.29399/npa.27419)
 119. Chiang KJ, Tsai JC, Liu D, Lin CH, Chiu HL, Chou KR: Efficacy of cognitive-behavioral therapy in patients with bipolar disorder: a meta-analysis of randomized controlled trials. *PLoS One.* 2017, 12:e0176849. [10.1371/journal.pone.0176849](https://doi.org/10.1371/journal.pone.0176849)
 120. Perry A, Tarrier N, Morriss R, McCarthy E, Limb K: Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. *BMJ.* 1999, 318:149-53. [10.1136/bmj.318.7177.149](https://doi.org/10.1136/bmj.318.7177.149)
 121. Rabelo JL, Cruz BF, Ferreira JD, Viana BM, Barbosa IG: Psychoeducation in bipolar disorder: a systematic

- review. *World J Psychiatry*. 2021, 11:1407-24. [10.5498/wjpv11.i12.1407](https://doi.org/10.5498/wjpv11.i12.1407)
122. Buizza C, Candini V, Ferrari C, et al.: The long-term effectiveness of psychoeducation for bipolar disorders in mental health services. A 4-year follow-up study. *Front Psychiatry*. 2019, 10:873. [10.3389/fpsyg.2019.00873](https://doi.org/10.3389/fpsyg.2019.00873)
 123. Steele AL, Waite S, Egan SJ, Finnigan J, Handley A, Wade TD: Psycho-education and group cognitive-behavioural therapy for clinical perfectionism: a case-series evaluation. *Behav Cogn Psychother*. 2013, 41:129-43. [10.1017/S1352465812000628](https://doi.org/10.1017/S1352465812000628)
 124. Schaub A, Hippus H, Möller HJ, Falkai P: Psychoeducational and cognitive behavioral treatment programs: implementation and evaluation from 1995 to 2015 in Kraepelin's former hospital. *Schizophr Bull*. 2016, 42 Suppl 1:S81-9. [10.1093/schbul/sbw057](https://doi.org/10.1093/schbul/sbw057)
 125. Miklowitz DJ, Scott J: Psychosocial treatments for bipolar disorder: cost-effectiveness, mediating mechanisms, and future directions. *Bipolar Disord*. 2009, 11:2:110-22. [10.1111/j.1399-5618.2009.00715.x](https://doi.org/10.1111/j.1399-5618.2009.00715.x)
 126. Altmann U, Thielemann D, Zimmermann A, et al.: Outpatient psychotherapy improves symptoms and reduces health care costs in regularly and prematurely terminated therapies. *Front Psychol*. 2018, 9:748. [10.3389/fpsyg.2018.00748](https://doi.org/10.3389/fpsyg.2018.00748)
 127. Cuijpers P: Targets and outcomes of psychotherapies for mental disorders: an overview. *World Psychiatry*. 2019, 18:276-85. [10.1002/wps.20661](https://doi.org/10.1002/wps.20661)